Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nivolumab + ipilimumab + High Intensity Focused Ultrasound Histotripsy
- Development stage
- Phase 4
- Lead developer
- University Medical Center Utrecht
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Nivolumab + ipilimumab + High Intensity Focused Ultrasound Histotripsy (HIFU-HT) is an investigational combination therapy being evaluated in the iFOCUS Phase 1 clinical trial at UMC Utrecht for the treatment of metastatic or unresectable cancer. This regimen combines two immune checkpoint inhibitors—nivolumab, a monoclonal antibody targeting the programmed death-1 (PD-1) receptor, and ipilimumab, a monoclonal antibody targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)—with HIFU-HT, a non-invasive medical device technology that uses focused ultrasound to mechanically disrupt tumor tissue (histotripsy). The goal of this combination is to enhance the systemic anti-tumor immune response by using HIFU-HT to release tumor antigens and create a pro-inflammatory environment, potentially overcoming resistance to immunotherapy in patients with metastatic or unresectable solid tumors that have progressed after standard treatment.
- Other names
- nivolumab + ipilimumab + HIFU-HTICI + HIFU-HT
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on nivolumab + ipilimumab + High Intensity Focused Ultrasound Histotripsy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nivolumab + ipilimumab + High Intensity Focused Ultrasound Histotripsy.